BioXcel Therapeutics (BTAI) PT Lowered to $7 at BofA Securities

March 13, 2024 6:13 AM

BofA Securities analyst Geoff Meacham lowered the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $7.00 (from $8.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found